Top Markets
#1 Cortex Cortex +32.77%
#2 MarsCoin MarsCoin +9.41%
#3 EXOD EXOD +9.04%
#4 Akedo Akedo +8.36%
#5 peaq peaq +8.33%
#6 Solstice Solstice +8.02%
#7 龙虾 (Lobster) 龙虾 (Lobster) +6.95%
#8 Official Trump Official Trump +6.27%
#9 Peapods Finance Peapods Finance +6.22%
#10 DexNet DexNet +5.76%
Coin of the day
Cortex Cortex
Settings
Language
ENGLISH
Currency
USD
Theme
HBM Holdings Limited HBM Holdings Limited

HBM Holdings Limited

2142
Rank in Stocks #7277
HBM Holdings Limited is a clinical-stage biopharmaceutical enterprise focused... HBM Holdings Limited is a clinical-stage biopharmaceutical enterprise focused on identifying and developing unique antibody-based treatments for a variety of immunological conditions and cancers. The company's pipeline includes several promising assets. In immunology, Batoclimab (HBM9161) is a human monoclonal antibody specifically designed to bind and inhibit the neonatal fragment crystallizable receptor, while Tanfanercept (HBM9036) is under development to address moderate to severe dry eye disease. For oncology, HBM Holdings is advancing various therapies, such as HBM7008, a bispecific antibody targeting tumor-associated antigens, and HBM4003, a human anti-CTLA-4 antibody. Additional cancer candidates in their portfolio include HBM9302 for breast and gastric cancers, HBM7020 for multiple myeloma, and a suite of treatments—HBM1007, HBM1029, HBM7015, HBM7008, and HBM1022—geared towards solid tumors. Furthermore, HBM9022 is being developed to treat SARS-COV-2. Operating globally, HBM Holdings has a presence in Mainland China, the United States, Europe, and other international markets. The company also fosters strategic partnerships for antibody-drug conjugate (ADC) projects with LegoChem Biosciences Inc. and Duality Biotherapeutics, Inc. HBM Holdings Limited was founded in 2016 and is based in Shanghai, People's Republic of China.
Share Price
$1.93
Market Cap
$1.63B
Change (1 day)
-7.24%
Change (1 year)
18.71%
Country
CN
Trade HBM Holdings Limited (2142)

Category

Healthcare
Operating Margin for HBM Holdings Limited (2142)
Operating Margin as of 2026 TTM: 0.00%
According to HBM Holdings Limited latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for HBM Holdings Limited from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.72% -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.